Cargando…

Review of pharmacotherapy for smoking cessation in patients with schizophrenia

Smoking cessation is a chronic issue surrounding individuals with schizophrenia. It is estimated that up to 90% of patients diagnosed with schizophrenia smoke cigarettes. The purpose of this article is to provide a nonsystematic review of the efficacy of smoking cessation interventions as well as to...

Descripción completa

Detalles Bibliográficos
Autores principales: Shawen, Avery E., Drayton, Shannon J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: College of Psychiatric & Neurologic Pharmacists 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6007740/
https://www.ncbi.nlm.nih.gov/pubmed/29955550
http://dx.doi.org/10.9740/mhc.2018.03.078
Descripción
Sumario:Smoking cessation is a chronic issue surrounding individuals with schizophrenia. It is estimated that up to 90% of patients diagnosed with schizophrenia smoke cigarettes. The purpose of this article is to provide a nonsystematic review of the efficacy of smoking cessation interventions as well as to explore the potential neuropsychiatric adverse effects of these agents in patients with schizophrenia. Eighteen studies were found and included in the review. Overall, nicotine replacement therapy, bupropion, and varenicline have all proven their effectiveness at either promoting smoking abstinence or a significant reduction in cigarette use.